NASDAQ:STIM Neuronetics (STIM) Stock Forecast, Price & News $2.71 -0.06 (-2.17%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.62▼$2.8550-Day Range$2.07▼$2.9352-Week Range$2.01▼$6.95Volume55,198 shsAverage Volume176,439 shsMarket Capitalization$77.10 millionP/E RatioN/ADividend YieldN/APrice Target$9.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Neuronetics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside256.7% Upside$9.67 Price TargetShort InterestHealthy1.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$556,473 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.29) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector228th out of 983 stocksSurgical & Medical Instruments Industry24th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.67, Neuronetics has a forecasted upside of 256.7% from its current price of $2.71.Amount of Analyst CoverageNeuronetics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.18% of the float of Neuronetics has been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently decreased by 19.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STIM. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Neuronetics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have bought 282.21% more of their company's stock than they have sold. Specifically, they have bought $556,473.00 in company stock and sold $145,593.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions62.90% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($1.29) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neuronetics (NASDAQ:STIM) StockNeuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.Read More Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address STIM Stock News HeadlinesMay 31, 2023 | americanbankingnews.comComparing Neuronetics (NASDAQ:STIM) and Rosecliff Acquisition Corp I (NASDAQ:RCLF)May 26, 2023 | finance.yahoo.comNeuronetics Announces Increased TMS Access Through BlueCross BlueShield Of MichiganJune 4, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 24, 2023 | finance.yahoo.comNeuronetics to Present at the William Blair 43rd Annual Growth Stock ConferenceMay 23, 2023 | technews.tmcnet.comNew Depression Barometer Survey Shows Patients Are Stopping Treatment Due to DissatisfactionMay 15, 2023 | finance.yahoo.comNeuronetics Wins 2023 Bell Seal for Workplace Mental HealthMay 14, 2023 | americanbankingnews.comWilliam Blair Weighs in on Neuronetics, Inc.'s Q2 2023 Earnings (NASDAQ:STIM)May 12, 2023 | msn.comJMP Securities Reiterates Neuronetics (STIM) Market Outperform RecommendationJune 4, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 10, 2023 | marketwatch.comTMS (Transcranial Magnetic Stimulation) Coil Market Forecast 2023-2030May 9, 2023 | finance.yahoo.comNeuronetics Reports Record First Quarter 2023 Financial and Operating ResultsMay 8, 2023 | finance.yahoo.comNeuronetics Receives MDSAP Certification and CE Mark Certification under New MDRMay 3, 2023 | finance.yahoo.comNeuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual MeetingMay 2, 2023 | finance.yahoo.comNeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness MonthMay 2, 2023 | seekingalpha.comNeuronetics names Lisa Metzner-Rosas as CMOMay 1, 2023 | finance.yahoo.comNeuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing OfficerApril 28, 2023 | finance.yahoo.comNeuronetics Announces Expanded TMS Access through United HealthCareApril 25, 2023 | finance.yahoo.comNeuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference CallApril 18, 2023 | finance.yahoo.comFurther weakness as Neuronetics (NASDAQ:STIM) drops 11% this week, taking one-year losses to 25%April 13, 2023 | finance.yahoo.comNeuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS TherapyApril 8, 2023 | marketwatch.comNeuroStar(R) Advanced Therapy Enhanced With Wi-Fi CapabilitiesApril 6, 2023 | finance.yahoo.comNeuroStar® Advanced Therapy Enhanced With Wi-Fi CapabilitiesApril 4, 2023 | finance.yahoo.comNeuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory NoteMarch 30, 2023 | americanbankingnews.comNeuronetics, Inc. (NASDAQ:STIM) Short Interest UpdateMarch 27, 2023 | marketwatch.comTMS (Transcranial Magnetic Stimulation) Coil Market Major Players, Anlysis and Forecast till 2031March 23, 2023 | americanbankingnews.comNeuronetics, Inc. (NASDAQ:STIM) Major Shareholder Acquires $151,008.80 in StockMarch 16, 2023 | finance.yahoo.comNeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PASee More Headlines STIM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STIM Company Calendar Last Earnings5/09/2023Today6/04/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees175Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.67 High Stock Price Forecast$12.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+256.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,160,000.00 Net Margins-55.34% Pretax Margin-55.35% Return on Equity-62.22% Return on Assets-31.85% Debt Debt-to-Equity Ratio0.76 Current Ratio5.36 Quick Ratio4.76 Sales & Book Value Annual Sales$65.21 million Price / Sales1.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book1.59Miscellaneous Outstanding Shares28,450,000Free Float26,376,000Market Cap$77.10 million OptionableNot Optionable Beta1.93 Key ExecutivesKeith J. SullivanPresident, Chief Executive Officer & DirectorStephen FurlongChief Financial Officer, Treasurer & Executive VPCory AndersonSVP- Research & Development & Clinical AffairsW. Andrew MacanSecretary, CCO, EVP & General CounselSara GrubbsChief Revenue Officer & Senior Vice PresidentKey CompetitorsProSomnusNASDAQ:OSALyra TherapeuticsNASDAQ:LYRADelcath SystemsNASDAQ:DCTHAkiliNASDAQ:AKLIMeihua International Medical TechnologiesNASDAQ:MHUAView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCSold 84,546 shares on 6/1/2023Ownership: 0.636%JPMorgan Chase & Co.Bought 7,749 shares on 5/18/2023Ownership: 0.060%Geode Capital Management LLCBought 26,204 shares on 5/16/2023Ownership: 0.899%State Street CorpBought 11,800 shares on 5/16/2023Ownership: 0.359%Squarepoint Ops LLCBought 17,253 shares on 5/16/2023Ownership: 0.061%View All Insider TransactionsView All Institutional Transactions STIM Stock - Frequently Asked Questions Should I buy or sell Neuronetics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STIM shares. View STIM analyst ratings or view top-rated stocks. What is Neuronetics' stock price forecast for 2023? 2 brokers have issued twelve-month price objectives for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.67 in the next year. This suggests a possible upside of 256.7% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts. How have STIM shares performed in 2023? Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM shares have decreased by 60.6% and is now trading at $2.71. View the best growth stocks for 2023 here. Are investors shorting Neuronetics? Neuronetics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 304,200 shares, a decrease of 19.8% from the April 30th total of 379,400 shares. Based on an average daily trading volume, of 253,300 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.2% of the company's shares are sold short. View Neuronetics' Short Interest. When is Neuronetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our STIM earnings forecast. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.01. The company had revenue of $15.54 million for the quarter, compared to analysts' expectations of $15.11 million. Neuronetics had a negative net margin of 55.34% and a negative trailing twelve-month return on equity of 62.22%. What ETF holds Neuronetics' stock ? iShares Neuroscience and Healthcare ETF holds 2,895 shares of STIM stock, representing 0.14% of its portfolio. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics issued an update on its second quarter 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.00 million-$18.00 million, compared to the consensus revenue estimate of $17.30 million. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST). When did Neuronetics IPO? (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. What is Neuronetics' stock symbol? Neuronetics trades on the NASDAQ under the ticker symbol "STIM." Who are Neuronetics' major shareholders? Neuronetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cannell Capital LLC (10.99%), Silvercrest Asset Management Group LLC (3.41%), Balyasny Asset Management L.P. (3.25%), Acadian Asset Management LLC (1.46%), BlackRock Inc. (1.33%) and Dimensional Fund Advisors LP (1.31%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neuronetics' stock price today? One share of STIM stock can currently be purchased for approximately $2.71. How much money does Neuronetics make? Neuronetics (NASDAQ:STIM) has a market capitalization of $77.10 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. How many employees does Neuronetics have? The company employs 175 workers across the globe. How can I contact Neuronetics? Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206. This page (NASDAQ:STIM) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.